Toe nail fungus Barrier Therapeutics ends patient enrollment for Hyphanox (Pharmaceutical Business Review)

Barrier Therapeutics has completed patient enrollment for its pivotal Phase III clinical study of Hyphanox, an oral formulation of the antifungal agent itraconazole, for the treatment of toenail onychomycosis.